Chronic myeloid leukemia in the imatinib era

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The results of imatinib (Gleevec) (formerly STI571) therapy for chronic myeloid leukemia (CML) have continued to improve and have surpassed almost everyone's predictions. However, the long-term results with imatinib and its ability to cure CML as a single agent are unknown. These issues will be discussed along with potential strategies to improve the cure rate, using imatinib as a building block to achieve this goal.

Original languageEnglish (US)
Pages (from-to)1-3
Number of pages3
JournalSeminars in Hematology
Volume40
Issue number2 SUPPL. 2
DOIs
StatePublished - Apr 2003

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Chronic myeloid leukemia in the imatinib era'. Together they form a unique fingerprint.

  • Cite this